Multiple myeloma is the second most common hematologic malignancy, but there is a treatment gap for patients with disease ...

Multiple Myeloma is a type of blood cancer that develops in plasma ... and advanced therapies like blood stem cell ...

Multiple myeloma is a type of cancer where plasma ... In a 2017 study, researchers examined the impact of CRAB symptoms on the survival of people with myeloma receiving new types of medications.

If approved by the FDA, Darzalex Faspro may be the first treatment for smoldering multiple myeloma as compared to treating the disease once it progresses.

J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...

The CAR-T cell therapy Carvykti has been shown to be effective among patients outside the confines of a clinical trial.

The marketing applications with the EMA and FDA are for J&J and partner Genmab's Darzalex Faspro version of the anti-CD38 ...

The FDA has granted LBL-034 orphan drug designation for relapsed/refractory multiple myeloma treatment. LBL-034 has received ...

A video of the late folk singer Sharda Sinha is doing rounds on the internet wherein she can be seen singing a Chhath song ...

Truist Securities analyst Asthika Goonewardene in an investor note said data for anito-cel—particularly its safety ...

Binod Dhakal, MD, MS, discusses some of the next steps for evaluating ciltacabtagene autoleucel in multiple myeloma and the CARTITUDE-4 trial.

Johnson & Johnson seeks US & EU approvals for Darzalex Faspro/Darzalex as subcutaneous monotherapy for high-risk smoldering multiple myeloma: Raritan, New Jersey Monday, November ...